Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event
A retrospective study of 16 women treated between 2015 and 2018 described one woman [age not stated], who developed neutropenia following treatment with palbociclib and radiotherapy for metastatic breast cancer [route, dosage, duration of treatment to reaction onset and outcome not stated].
Author comment: "Despite this potential benefit, clinicians seldom use this combination due to fear that RT may exacerbate palbociclib toxicity, particularly hematologic." "Following RT, 5 (31.3%), 1 (6.3%), and 3 (18.8%) patients were leukopenic, neutropenic, and thrombocytopenic, respectively."
Reference
Chowdhary M, et al. Safety and Efficacy of Palbociclib (CDK4/6 inhibitor) and Radiotherapy in Metastatic Breast Cancer Patients: Initial Results of a Novel Combination. International Journal of Radiation Oncology, Biology, Physics 105 (Suppl.): E2, No. 1, Sep 2019. Available from: URL: http://doi.org/10.1016/j.ijrobp.2019.06.619 [abstract] - USA
Rights and permissions
About this article
Cite this article
Palbociclib. Reactions Weekly 1769, 341 (2019). https://doi.org/10.1007/s40278-019-67355-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-019-67355-x